Table 3.

Registered Topical Therapy Trials for Oral cGvHD

Trial	Center	ClinicalTrials.gov Identifier	Agent	Design	Premise	Target Population
Dexamethasone to Prevent Oral cGVHD	National Institutes of Health, NHLBI, Bethesda, MD	NCT00391170	topical dexamethasone 0.01% oral rinse	Randomized double blind	Prevention of cGvHD	70–90 d. post transplant, no oral cGVHD
Topical Dexamethasone and Tacrolimus for the Treatment of Oral cGVHD	Brigham and Women’s Hospital, Boston, MA	NCT00686855	tacrolimus oral rinse or dexamethasone oral rinse	Open label, randomized	Efficacy of Treatment for oral GvHD	Post transplant with mild to moderate oral cGvHD sympotoms
Efficacy and Safety Study of Budesonide to Treat Oral cGvHD	University of Regensburg, Regensberg, Germany; The Hebrew University, Jerusalem, Israel	NCT00887263	Budesonide 3 mg Effervescent Tablet	Randomized double blind	Efficacy of Treatment for oral GvHD	Post transplant with mild to severe oral cGvHD sympotoms
Clobetasol for Oral GVHD	National Institutes of Health, NCI, Bethesda, MD	NCT01557517	topical clobetasol 0.05% oral rinse	Randomized double blind	Efficacy of Treatment for oral GvHD	Post transplant with moderate to severe oral cGvHD sympotoms

Information was extracted from www.clinicaltrials.gov using search terms “oral “ and “GVHD.” Current as of August 27, 2012